Eigen Bio Chief Science Officer Kristin Gleitsman describes a model-guided approach to finding biological targets and building therapeutic programs from patient-response evidence. She discusses the company's Eigen-1 RNA model, early analyses, and the proposed feedback cycle between experiments, clinical data, and new predictions. Judges ask about development pace, revenue models, target discovery, and precision therapeutics.
More from the studio
1:10AI x Bio Pitch Contest
A short look at the September 29 AI x Bio Pitch Contest in San Francisco, from company pitches to the award presentations.
9:25AI x Bio Pitch Contest — Optagon Labs
Khalil Kaddoura presents Optagon Labs' proposed AI-driven loop for drug optimization and lab testing.
7:19AI x Bio Pitch Contest — Umbra Bio
Paul Donohoue presents Umbra Bio's approach to multi-attribute protein design and answers the judges' questions.